Capoten, tablets 25 mg 40 pcs

Capotene is a hypotensive.

It is a highly specific competitive ACE inhibitor. Inhibits the conversion of angiotensin I to angiotensin II (a powerful vasoconstrictor).

Pharmacodynamics

Creases ROSS (post-load), preload and pulmonary vascular resistance; increases cardiac minute volume and exercise tolerance. With long-term use, it reduces severity of myocardial hypertrophy of the left ventricle, prevents progression of heart failure and slows development of left ventricular dilatation.

Pharmacokinetics

After oral administration, 75% of the drug is rapidly absorbed from the gastrointestinal tract. Cmax in blood plasma is reached after one hour. Simultaneous intake of food slows down absorption of the drug by 30-40%. Binding to blood proteins is 25-30%. T1/2 is less than 3 h and increases in renal insufficiency. More than 95% of the drug is excreted through the kidneys, 40-50% is excreted unchanged, the rest is excreted as metabolites.

Indications

Arterial hypertension (as monotherapy and in combination with other antihypertensive agents, especially with thiazide diuretics), chronic heart failure (as part of combined therapy), myocardial infarction (to treat patients with impaired left ventricular function after infarction, in stable clinical condition), diabetic nephropathy (microalbuminuria more than 30 mg/day) in insulin-dependent diabetes.

Active ingredient

Composition

Active substance:

captopril 25 mg.

How to take, the dosage

Doses of Capoten should be selected by a physician.

Ingestion, one hour before meals, 25-50 mg 2-3 times daily (but no more than 450 mg per day), for children the starting dose is 0.15-0.3 mg/kg (but no more than 6 mg/kg per day).

Interaction

Diuretics, vasodilators, ganglioblocators, adrenoblockers when used simultaneously increase the antihypertensive effect of Capoten.
Indomethacin and other NSAIDs, as well as clonidine may decrease the antihypertensive effect of Capoten.

Special Instructions

Caution should be exercised when prescribing Capotene in collagenosis due to increased risk of neutropenia and agranulocytosis.

When prescribing the drug in patients with significant water-electrolyte imbalance, this condition should be corrected. During treatment with Capoten, it is not recommended to take potassium-saving diuretics or potassium preparations, especially in patients with significant renal impairment.

The angioedema of the extremities, face, lips, mucous membranes, tongue, pharynx or larynx is observed in patients when using ACE inhibitors, including captopril. If the swelling is limited to the face and lips, this condition usually subsides after discontinuation of the drug. Antihistamines may be used to relieve clinical symptoms.

Patients should be monitored by a physician until symptoms disappear. If swelling involves the tongue, pharynx or larynx with danger of airway obstruction, 0.5 ml of 0.1% adrenaline solution should be injected intravenously.

A low-sodium diet is indicated during treatment with Capoten.

Capotene may cause a false-positive urine test for acetone.

Pediatric use

The safety and effectiveness in children have not been studied.

Contraindications

Hypersensitivity in history (including history of other ACE inhibitors). to other ACE inhibitors), Quincke’s edema (hereditary or associated with a history of ACE inhibitors use), marked renal and hepatic dysfunction, hyperkalemia, bilateral renal artery stenosis or stenosis of the artery of the sole kidney with progressive azotemia, conditions after renal transplantation, aortic stenosis and similar obstructive changes impeding blood flow, pregnancy, breast-feeding period.

Side effects

Cardiovascular system: orthostatic hypotension, tachycardia, peripheral edema.

Respiratory system: dry cough, bronchospasm, pulmonary edema.

Allergic reactions: angioedema of the extremities, face, lips, mucous membranes, tongue, pharynx or larynx.

Water-electrolyte balance: hyperkalemia (most likely in renal failure), hyponatremia (most often in salt-free diet and concomitant use of diuretics.

Urinary system disorders: proteinuria, increased plasma urea nitrogen and creatinine, acidosis.

Hematopoietic system disorders: in rare cases – neutropenia, agranulocytosis, thrombocytopenia and anemia, positive test for antibodies to nuclear antigen. In patients with normal renal function (CK less than 1.6 mg/dL) in the absence of other complicating factors, neutropenia was observed in 0.02% of cases.

Digestive system disorders: reversible and usually self-liquidating taste disorder, dry mouth, aphthous stomatitis; rarely – abdominal pain, diarrhea, gum hyperplasia, hepatitis, increased level of liver plasma transaminases, hyperbilirubinemia.

Dermatological reactions: maculopapular rash, usually accompanied by itching and in rare cases – by increase in body temperature; hyperemia, vesicular or bullous rash, erythema (including Stevens-Johnson syndrome), photosensitization.

CNS and peripheral nervous system disorders: headache, dizziness, ataxia, paresthesia, somnolence, visual disorders.

Overdose

Symptoms: marked decrease in BP.

Treatment: administration of plasma substitute drugs and hemodialysis are effective.

Similarities